Catalent Invests $5.5 Million to Increase Clinical Storage Capacity at its Philadelphia Site
SOMERSET, N.J.-September 15, 2017
-Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it is investing $5.5 million at its 200,000+ square foot Philadelphia, Pennsylvania site to provide additional clinical packaging and storage capacity. The 22,000-square foot expansion will see a 40 percent increase in pallet space for both refrigerated and ambient storage, the addition of multiple cold chain packaging areas, and a new clinical label control area. The building will also feature a new state-of-the-art environmental monitoring and building management system which is being installed across the Philadelphia campus. All work is scheduled to be completed and validated by November 2017. “This project involved renovating a previously vacant building within our Philadelphia campus to bring it up to Catalent’s stringent facility standards,” commented Wetteny Joseph, Catalent’s President, Clinical Supply Services. “Not only have we added significant pallet capacity for our customers’ large-scale clinical studies today, but have secured the space necessary for future expansion as well.” Catalent currently supports the clinical trial supply needs of many pharmaceutical and biopharmaceutical organizations, including the top 25 pharmaceutical companies, and more than 300 small innovators from all over the world. Services include direct comparator sourcing, blinding and manufacturing, primary and secondary packaging, returns and clinical supplies management.
About Catalent
Catalent is a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com
More products. Better treatments. Reliably supplied.™
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
